Showing 1921-1930 of 5660 results for "".
PsO Many Options: The Expanded Psoriasis Landscape
https://practicaldermatology.com/topics/psoriasis/pso-many-options-the-expanded-psoriasis-landscape/18749/By Jeffrey Weinberg, MD and Seemal R. Desai, MDWith many new therapies coming out in oral, topical, and biologic forms, there are fewer unmet needs in psoriasis management now than ever before. Dr. Weinberg navigates the therapeutic landscape.Treatment Considerations for Hyperpigmentation
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/treatment-considerations-for-hyperpigmentation/18830/Seemal R. Desai, MD and Marta I. Rendon, MD discuss their treatment protocols for hyperpigmentation—from prescriptions and cosmeceuticals to lasers and peels. Noting that hyperpigmentation is a chronic, life-long condition, they emphasize the importance of vehicle consideration in enhancing efficacyIntegrity With Industry
https://practicaldermatology.com/programs/practical-dermatology/program-name/39883/Former Chair of the Board of Directors for the National Psoriasis Foundation Colby Evans, MD, provides an update on the SAFE Step Act, and Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, is joined by Jules Lipoff, Clinical Associate Professor (Adjunct) in the Lewis Katz School of MDermWireTV: ASDS Meeting Highlights; Daxxify Data; PA Week
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-asds-meeting-highlights-daxxify-data-pa-week/20147/ASDS speakers address aesthetic advancements, skin cancer, and DEI with Joel L. Cohen, MD, Sherrif Ibrahim, MD, and Jeanine Downie, MD. On the heels of FDA approval of Revance’s Daxxify, data published in the Aesthetic Surgery Journal demonstrate the efficacy of DaxibotulinumtoxinA for patients of dSocial media marketing trends for 2022 and beyond
https://practicaldermatology.com/topics/practice-management/social-media-marketing-trends-for-2022-and-beyond/20095/Social media is no longer the new frontier in digital marketing. It is a vital part of daily life for much of your audience. That means it is an indispensable part of a good marketing strategy for your dermatology practice. This short video from Ekwa Marketing (www.ekwa.com) covers the latest trendsScientifically Speaking: New Directions in Acne Management, Part 2
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-new-directions-in-acne-management-part-2/19950/From the optimal, safe use of isotretinoin to the proper role for systemic antibiotics and beyond, there are multiple areas of systemic acne care that deserve attention. In the second of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, MD; Linda Stein Gold, MD; and Emil Tanghetti, MD aAn Exciting Year in Dermatology
https://practicaldermatology.com/topics/psoriasis/an-exciting-year-in-dermatology/19929/From new topicals to novel systemic agents, several treatments may be coming to the market in the next two years, while existing therapies may see label expansions. Bruce Strober, MD, PhD offers a look at new MOAs and the evidence for their use.DermWireTV: AAD Virtual Data Highlights, Cynosure Consumer Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aad-virtual-data-highlights-cynosure-consumer-data/19818/The American Academy of Dermatology 2020 VMX Virtual Conference shines a light on fresh data from UCB, Leo Pharma, Lilly and Dermira, and Soliton. Cassiopea reports long-term data for Clascoterone. Zilxi from Menlo and Foamix approved for rosacea. Cynosure reports positive cosmetic consumer outlookDermWireTV: Allē Launches; Arazlo Cleared; BTL Files Suit
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-alle-launches-arazlo-cleared-btl-files-suit/19714/More than 10 Years and 6 million members later, the Brilliant Distinctions program is being relaunched with a new name and a new app: Allē. Arazlo Lotion 0.045%, the first lotion formulation of tazarotene, is now FDA approved for the topical treatment of acne vulgaris in patients nine years of age aDermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDA ac